

Earlier time to hemostasis is associated with decreased mortality and rate of complications: Results from the Pragmatic Randomized Optimal Platelet and Plasma Ratio trial

Ronald Chang, MD, Jeffrey D. Kerby, MD, PhD, Kyle J. Kalkwarf, MD, Gerald Van Belle, PhD, Erin E. Fox, PhD, Bryan A. Cotton, MD, MPH, Mitchell J. Cohen, MD, Martin A. Schreiber, MD, Karen Brasel, MD, MPH, Eileen M. Bulger, MD, Kenji Inaba, MD, Sandro Rizoli, MD, Jeanette M. Podbielski, BSN, Charles E. Wade, PhD, John B. Holcomb, MD, and PROPPR Study Group, Houston, Texas

AAST Continuing Medical Education Article

Accreditation Statement


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Surgeons and the American Association for the Surgery of Trauma. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

The American College of Surgeons designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Of the AMA PRA Category 1 Credit™ listed above, a maximum of 1 credit meets the requirements for self-assessment.

Credits can only be claimed online



AMERICAN COLLEGE OF SURGEONS

Inspiring Quality:

Highest Standards, Better Outcomes

100+ years

Objectives

After reading the featured articles published in the *Journal of Trauma and Acute Care Surgery*, participants should be able to demonstrate increased understanding of the material specific to the article. Objectives for each article are featured at the beginning of each article and online. Test questions are at the end of the article, with a critique and specific location in the article referencing the question topic.

Claiming Credit

To claim credit, please visit the AAST website at <http://www.aast.org/> and click on the "e-Learning/MOC" tab. You must read the article, successfully complete the post-test and evaluation. Your CME certificate will be available immediately upon receiving a passing score of 75% or higher on the post-test. Post-tests receiving a score of below 75% will require a retake of the test to receive credit.

System Requirements

The system requirements are as follows: Adobe® Reader 7.0 or above installed; Internet Explorer® 7 and above; Firefox® 3.0 and above, Chrome® 8.0 and above, or Safari™ 4.0 and above.

Questions

If you have any questions, please contact AAST at 800-789-4006. Paper test and evaluations will not be accepted.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this journal activity, must ensure that anyone in a position to control the content of *J Trauma Acute Care Surg* articles selected for CME credit has disclosed all relevant financial relationships with any commercial interest. Disclosure forms are completed by the editorial staff, associate editors, reviewers, and all authors. The ACCME defines a 'commercial interest' as "any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients." "Relevant" financial relationships are those (in any amount) that may create a conflict of interest and occur within the 12 months preceding and during the time that the individual is engaged in writing the article. All reported conflicts are thoroughly managed in order to ensure any potential bias within the content is eliminated. However, if you perceive a bias within the article, please report the circumstances on the evaluation form.

Please note we have advised the authors that it is their responsibility to disclose within the article if they are describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

Disclosures of Significant Relationships with Relevant Commercial Companies/Organizations by the Editorial Staff

Ernest E. Moore, Editor: PI, research support and shared U.S. patents Haemonetics; PI, research support, Instrumentation Laboratory, Inc.; Co-founder, Thrombo Therapeutics. Associate Editors David Hoyt, Ronald V. Maier and Steven Shackford have nothing to disclose. Editorial staff and Angela Sauaia have nothing to disclose.

Author Disclosures

Martin A. Schreiber, Velico Medical: Money, Haemonetics: Money, Arsenal Medical: Money. Jeanette M. Podbielski, Co-author – Masimo: Money, Prytime Medical: Money, Charles E. Wade, Co-author – Money, Decisio LLC-stock: Money, Masimo: Money, Grifols: Money, John B. Holcomb, Co-author - Decisio Health: Money, Terumo BCT: Money, Decisio Health: Money.

Reviewer Disclosures

The reviewers have nothing to disclose.

Cost

For AAST members and *Journal of Trauma and Acute Care Surgery* subscribers there is no charge to participate in this activity. For those who are not a member or subscriber, the cost for each credit is \$25.

BACKDROP:	Clinicians intuitively recognize that faster time to hemostasis is important in bleeding trauma patients, but these times are rarely reported.
METHODS:	Prospectively collected data from the Pragmatic Randomized Optimal Platelet and Plasma Ratios trial were analyzed. Hemostasis was predefined as no intraoperative bleeding requiring intervention in the surgical field or resolution of contrast blush on interventional radiology (IR). Patients who underwent an emergent (within 90 minutes) operating room (OR) or IR procedure were included. Mixed-effects Poisson regression with robust error variance (controlling for age, Injury Severity Score, treatment arm, injury mechanism, base excess on admission [missing values estimated by multiple imputation], and time to OR/IR as fixed effects and study site as a random effect) with modified Bonferroni corrections tested the hypothesis that decreased time to hemostasis was associated with decreased mortality and decreased incidence of acute kidney injury (AKI), acute respiratory distress syndrome (ARDS), multiple-organ failure (MOF), sepsis, and venous thromboembolism.
RESULTS:	Of 680 enrolled patients, 468 (69%) underwent an emergent procedure. Patients with decreased time to hemostasis were less severely injured, had less deranged base excess on admission, and lower incidence of blunt trauma (all $p < 0.05$). In 408 (87%) patients in whom hemostasis was achieved, every 15-minute decrease in time to hemostasis was associated with decreased 30-day mortality (RR, 0.97; 95% confidence interval [CI], 0.94–0.99), AKI (RR, 0.97; 95% CI, 0.96–0.98), ARDS (RR, 0.98; 95% CI, 0.97–0.99), MOF (RR, 0.94; 95% CI, 0.91–0.97), and sepsis (RR, 0.98; 95% CI, 0.96–0.99), but not venous thromboembolism (RR, 0.99; 95% CI, 0.96–1.03).
CONCLUSION:	Earlier time to hemostasis was independently associated with decreased incidence of 30-day mortality, AKI, ARDS, MOF, and sepsis in bleeding trauma patients. Time to hemostasis should be considered as an endpoint in trauma studies and as a potential quality indicator. (<i>J Trauma Acute Care Surg.</i> 2019;87: 342–349. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.)
LEVEL OF EVIDENCE:	Therapeutic/care management, level III.
KEY WORDS:	Hemorrhage; trauma; massive transfusion.

Hemorrhage is the leading cause of preventable trauma mortality^{1–3} with median time to exsanguination of 2 hours to 3 hours after hospital arrival.^{4,5} Optimal treatment of the hemorrhaging trauma patient includes transfusion of a balanced ratio of blood products and measures to rapidly acquire mechanical hemorrhage control, that is, hemostasis.⁶ Clinicians intuitively recognize that minimization of blood loss by more rapidly obtaining hemostasis reduces physiologic derangement and ischemic organ injury, thereby improving patient outcomes. Several studies have reported that minimizing times to laparotomy,^{7,8} interventional radiology (IR),⁹ and plasma and platelet transfusion (hemostatic resuscitation)^{4,10,11} are associated with improved outcomes in trauma patients, likely by minimizing the time to hemostasis and degree of blood loss. However, time to hemostasis is not routinely reported.¹² The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial found that bleeding trauma patients randomized to high (1:1:1) ratios of plasma and

platelets to red blood cells (RBCs) were more likely to have achieved hemostasis and less likely to have died from hemorrhage within the first 24 hours compared to patients randomized to a low (1:1:2) ratio, although there were no differences in 24-hour or 30-day mortality.⁵ In patients achieving hemostasis, the time from hospital arrival to hemostasis was similar between treatment arms (median, 144 minutes vs. 131 minutes; $p = 0.17$). We hypothesized that early achievement of hemostasis was independently associated with reduced mortality and risk of complications.

METHODS

Patients and Data Collection

This was a prespecified secondary analysis of the PROPPR study, a pragmatic, phase 3, multicenter trial which randomized 680 bleeding trauma patients predicted to require massive transfusion to resuscitation with 1:1:1 versus 1:1:2 plasma to platelets to RBCs during a 17-month period in 2012 to 2013. This study was approved by the institutional review boards of all 12 participating sites.⁵

Definitions

Hemostasis was declared by the attending trauma surgeon and defined a priori as no intraoperative bleeding requiring intervention in the surgical field or resolution of contrast blush on IR. Active resuscitation was ended when hemostasis was achieved and the attending surgeon and anesthesiologist agreed that the patient was adequately resuscitated based on improving patient physiology (normalizing vital signs, increasing urine output, or decreasing vasopressor requirement). We included patients who underwent an emergent procedure defined as any operating room (OR) or IR procedure for hemorrhage control within 90 minutes of hospital arrival, consistent with previous studies.^{7,13} Severe injury was defined as Abbreviated Injury Scale score of 3 or greater. Definitions of complications were those from the primary article and were standardized across all institutions.⁵ Acute kidney injury (AKI) was defined as serum creatinine increase of $0.3 \text{ mg}\cdot\text{dL}^{-1}$ or greater or 50% or greater,

Submitted: June 27, 2017; Revised: January 21, 2019; Accepted: January 31 2019.

From the Center for Translational Injury Research (R.C., K.J.K., E.E.F., B.A.C., J.M.P., C.E.W., J.B.H.), University of Texas Health Science Center; Department of Surgery (R.C., K.J.K., E.E.F., B.A.C., C.E.W., J.B.H.), McGovern Medical School, Houston, Texas; Department of Surgery (J.D.K.), University of Alabama at Birmingham School of Medicine, Birmingham, Alabama; Department of Biostatistics and Environmental and Occupational Health Sciences (G.V.B.), University of Washington School of Medicine, Seattle, Washington; Department of Surgery (M.J.C.), University of Colorado School of Medicine, Denver, Colorado; Department of Surgery (M.A.S., K.B.), Oregon Health & Science University, Portland, Oregon; Department of Surgery (E.M.B.), University of Washington School of Medicine, Seattle, Washington; Department of Surgery (K.I.), University of Southern California School of Medicine, Los Angeles, California; and Department of Surgery (S.R.), University of Toronto, Toronto, Canada.

Presented at the 76th Annual Meeting of the American Association for the Surgery of Trauma, September 13–16, 2017 in Baltimore, MD.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jtrauma.com).

Address for reprints: Ronald Chang, MD, 6410 Fannin St. Suite 1100 Houston, TX 77030; email: ronald.chang@uth.tmc.edu.

DOI: 10.1097/TA.0000000000002263

glomerular filtration rate decrease of 25% or greater, or urine output less than $0.5 \text{ mL} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$. Acute respiratory distress syndrome (ARDS) was defined according to the Berlin criteria.¹⁴ Multiple-organ failure (MOF) was defined using the Denver MOF scoring system. Sepsis was defined as systemic inflammatory response syndrome and suspected or known infection. Venous thromboembolism (VTE) was defined as deep venous thrombosis identified by autopsy or imaging, or pulmonary embolism identified on computed tomography angiogram.

Statistical Analysis

Stata 14.1 (Stata Corp., College Station, TX) was used for all calculations. Data are summarized as median and interquartile range (IQR) or proportions as appropriate. Patients requiring emergent OR or IR were separated into groups based on time to hemostasis to facilitate univariate and sensitivity analyses. Patients were divided into quartiles based on time to hemostasis with a fifth group created for patients who did not achieve hemostasis. Nonparametric univariate comparisons of continuous data were performed using the Kruskal-Wallis test. Comparisons of categorical data were performed with χ^2 test or Fisher's exact test for categories with five or less expected members. Locally weighted scatterplot smoothing (LOWESS) was used to estimate the incidence of complications versus time to hemostasis.

Mixed-effects Poisson models with robust error variance (which have been previously used to analyze dichotomous outcomes)¹⁵ were used to analyze mortality at 24 hours and 30 days, as well as five inflammatory complications (AKI, ARDS, MOF, sepsis, and VTE) to test the hypothesis that decreased time to hemostasis was independently associated with improved outcomes. Of the 23 predefined complications analyzed in PROPPR, we chose the above complications to analyze in the present study because they were prevalent, clinically important, and thought to be potential consequences of the prolonged ischemia and increased inflammation secondary to delayed hemostasis. Of note, 6-hour mortality was not analyzed because only one patient who achieved hemostasis died within 6 hours of ED arrival. Unadjusted models controlled for study site as a random effect. Adjusted models controlled for study site as a random effect and the following as fixed effects: age, Injury Severity Score (ISS), injury mechanism, treatment arm, admission base excess, and time to OR/IR. These were selected because of their clinical significance and/or statistical significance at the 0.1 level on univariate analysis. Missing admission base excess data were estimated using multiple imputation with predictive mean matching using age, injury mechanism, and ISS as predictors. Modified Bonferroni corrections were performed to control

for multiple comparisons. Because these analyses use time to hemostasis as a continuous variable, only patients who achieved hemostasis were included. Sensitivity analyses were then performed which included patients who exsanguinated before hemostasis was achieved. A two-tailed alpha level of 0.05 was used for all statistical tests.

RESULTS

Summary of Hemostasis and Between-Site Comparisons

Of 680 patients enrolled, 468 (69%) underwent an emergent OR/IR procedure. These patients had greater incidence of severe abdominal injury (60% vs. 27%), decreased incidence of severe head injury (17% vs. 34%), and decreased incidence of traumatic brain injury–related death (6% vs. 17%) compared to those not undergoing an emergent OR/IR procedure (all $p < 0.01$).

Among patients undergoing emergent OR/IR, hemostasis was achieved in 87% ($n = 408$) with no significant differences between study sites on the χ^2 test (range, 71–91% per site; $p = 0.43$). We examined the time to emergent OR/IR, time from OR/IR to hemostasis, and overall time to hemostasis, which is schematically depicted in Figure 1. Time from OR/IR to hemostasis accounted for the majority of overall time to hemostasis (median, 77%; IQR, 63–87%). There were significant between-site differences in proportion of blunt trauma (range, 8–57%), use of emergent IR instead of OR (range, 0–20%), as well as time to emergent OR/IR, time from OR/IR to hemostasis, and overall time to hemostasis (Fig. 2, all $p < 0.05$). Overall time to hemostasis was significantly higher in blunt versus penetrating trauma (median, 139 minutes vs. 119 minutes, $p < 0.01$) and after IR versus OR (median, 184 minutes vs. 127 minutes, $p < 0.01$).

Demographics

Patients who underwent emergent OR/IR ($n = 468$, 69%) were divided into quartiles based on time to hemostasis (group 1, <90 minutes; group 2, 90 to 129 minutes; group 3, 130 to 183 minutes; group 4, >183 minutes). A fifth group was created for patients who did not achieve hemostasis. There were no differences in age, admission systolic blood pressure or heart rate, or treatment arm between groups (Table 1). Higher group number was associated with increased ISS, more deranged base excess on admission, and higher incidence of blunt trauma. Multiple imputation with predictive mean matching was used to estimate missing admission base excess in 45 (10%) patients




Figure 1. Schematic representation of overall time to hemostasis, which consists of time from hospital arrival to OR/IR and time from OR/IR to hemostasis.




Figure 2. Between-site comparisons for patients requiring emergent OR/IR (n = 468). Incidence of blunt (vs. penetrating) trauma varied significantly between sites. (A) Time from hospital arrival to emergent OR/IR, (B) time from emergent OR/IR to hemostasis, (C) and overall time to hemostasis, (D) also varied significantly between sites. Time from emergent OR/IR to hemostasis accounted for median 73% (IQR, 63%–87%) of overall time to hemostasis. * $p < 0.05$.

TABLE 1. Demographics of Patients Requiring Emergent OR/IR (N = 468)

Variables	Group 1 (n = 102)	Group 2 (n = 102)	Group 3 (n = 104)	Group 4 (n = 100)	Group 5 (n = 60)	p
Time to hemostasis, min	<90	90 to 129	130 to 183	>183	No hemostasis	—
Age, y	32 (24, 47)	31 (24, 43)	33 (24, 45)	32 (24, 48)	34 (24, 54)	0.57
ISS	20 (13, 34)	25 (14, 38)	26 (18, 36)	29 (19, 41)	34 (25, 45)	<0.01
Base excess, mEq/L	−7 (−11, −2)	−7 (−12, −4)	−7 (−12, −3)	−9 (−14, −6)	−17 (−19, −12)	<0.01
SBP, mm Hg	100 (79, 126)	106 (86, 130)	108 (86, 123)	104 (80, 130)	94 (78, 118)	0.17
Heart rate, bpm	113 (93, 131)	107 (92, 127)	120 (97, 133)	122 (102, 136)	113 (82, 136)	0.09
Blunt mechanism, n (%)	29 (28%)	36 (35%)	47 (45%)	46 (46%)	28 (47%)	0.03
Treatment arm, n (%)						0.67
1:1:1	53 (52%)	53 (52%)	46 (49%)	49 (49%)	33 (55%)	
1:1:2	49 (48%)	49 (48%)	58 (51%)	51 (51%)	27 (45%)	
Emergent OR, n (%)	101 (99%)	101 (99%)	97 (93%)	91 (91%)	59 (98%)	<0.01
Emergent IR, n (%)	1 (1%)	1 (1%)	7 (7%)	9 (9%)	1 (2%)	
Time from hospital arrival to OR/IR, min	20 (15, 28)	28 (19, 42)	31 (20, 57)	34 (21, 55)	25 (18, 45)	<0.01
Time from hospital arrival to hemostasis, min	69 (56, 80)	111 (101, 120)	152 (141, 165)	245 (210, 303)	—	—

TABLE 2. Outcomes of Patients Requiring Emergent OR/IR (N = 468)

Variables	Group 1 (n = 102)	Group 2 (n = 102)	Group 3 (n = 104)	Group 4 (n = 100)	Group 5 (n = 60)	p*
Transfusions during active resuscitation						<0.01
RBC (units)	5 (4, 8)	7 (4, 11)	8 (5, 14)	13 (8, 24)	20 (11, 37)	
Plasma (units)	2 (1, 3)	3 (2, 6)	5 (2, 10)	8 (4, 15)	14 (6, 20)	
Platelets (units)	1 (0, 1)	1 (0, 2)	1 (1, 2)	2 (1, 3)	3 (1, 4)	
Mortality at 6 h (n, %)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	55 (92%)	1.00
Mortality at 24 h (n, %)	1 (1%)	2 (2%)	2 (2%)	1 (%)	59 (98%)	1.00
Mortality at 30 d (n, %)	8 (8%)	8 (8%)	8 (8%)	15 (15%)	60 (100%)	0.25
Time to death (d)	3.6 (1.3, 6.3)	2.8 (0.8, 11.9)	7.1 (1.5, 18.5)	8.8 (2.5, 11.2)	0.09 (0.05, 0.15)	0.74
Cause of death** (n, %)						0.01
Exsanguination	0 (0%)	2 (2%)	3 (3%)	0 (0%)	60 (100%)	
TBI	6 (6%)	4 (4%)	3 (3%)	10 (10%)	4 (7%)	
Respiratory	1 (1%)	0 (0%)	1 (1%)	0 (0%)	3 (5%)	
MOF	0 (0%)	0 (0%)	4 (4%)	6 (6%)	0 (0%)	
Sepsis	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	
PE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
Other	1 (1%)	1 (1%)	0 (0%)	1 (1%)	1 (2%)	
ICU-free days	26 (17, 28)	25 (8, 27)	22 (11, 26)	16 (0, 25)	0 (0, 0)	<0.01
AKI (n, %)	13 (13%)	17 (17%)	29 (28%)	43 (43%)	2 (3%)	<0.01
ARDS (n, %)	10 (10%)	14 (14%)	23 (22%)	33 (33%)	5 (8%)	<0.01
MOF (n, %)	0 (0%)	2 (2%)	3 (3%)	14 (14%)	2 (3%)	<0.01
Sepsis (n, %)	21 (21%)	26 (25%)	43 (41%)	45 (45%)	0 (0%)	<0.01
VTE (n, %)	7 (7%)	10 (10%)	16 (15%)	14 (14%)	0 (0%)	0.20
Any complication† (n, %)	38 (37%)	38 (37%)	61 (59%)	72 (72%)	60 (100%)	<0.01

* For first four groups only.

** Not mutually exclusive.

† Includes mortality, AKI, ARDS, MOF, sepsis, or VTE.

TBI, traumatic brain injury; PE, pulmonary embolism.

using age, ISS, and injury mechanism as predictors. Distribution of base excess before and after imputation was unchanged.

Outcomes

Higher group number was associated with increased transfusion of blood products during active resuscitation, consistent with increased hemorrhage (Table 2). There were no significant differences in mortality or time to death between the first four groups, although cause of death was somewhat different. In contrast, patients in group 5 died quickly (median, 2.2 hours) from exsanguination. As group number increased, ICU-free days decreased and incidence of AKI, ARDS, MOF, and sepsis increased. The LOWESS regression was used to estimate the rate of any complication (mortality, AKI, ARDS, MOF, sepsis, or VTE) versus time to hemostasis (Fig. 3).

In 408 patients in whom hemostasis was achieved, mixed effects Poisson regression with robust error variance and modified Bonferroni corrections found that every 15-minute decrease in time to hemostasis was associated with decreased 30-day mortality (RR 0.97, 95% confidence interval [CI], 0.94–0.99, $p < 0.001$) and decreased incidence of AKI (RR 0.97, 95% CI 0.96–0.98, $p < 0.001$), ARDS (RR 0.98, 95% CI 0.97–0.99, $p < 0.01$), MOF (RR 0.94, 95% CI 0.91–0.97, $p < 0.001$), and sepsis (RR 0.98, 95% CI 0.96–0.99, $p < 0.001$), but not 24-hour mortality (RR 1.14, 95% CI 0.98–1.32, $p = 0.13$) or VTE (RR 0.99, 95% CI 0.96–1.03, $p = 0.73$). Results before and after adjustment for age, ISS, treatment arm, injury

mechanism, time to OR/IR, and admission base excess are summarized in Figure 4.

Diagnostic studies were performed (supplemental digital content, Figures 1–14, <http://links.lww.com/TA/B330>). In terms of global goodness-of-fit, chi-squared tests of the deviance statistic were not significant ($p > 0.05$). Visual inspection of deviance residuals versus predicted values revealed no outliers in




Figure 3. LOWESS regression of incidence of any complication (mortality, AKI, ARDS, MOF, sepsis, or VTE) versus time to hemostasis.




Figure 4. A–B, Mixed effects Poisson regression with robust error variance for patients requiring emergent OR/IR and who achieved hemostasis ($n = 408$). Unadjusted models (A) control for study site as a random effect. Adjusted models (B) control for age, ISS, injury mechanism, time to OR/IR, treatment group, and admission base excess as fixed effects and study site as a random effect. *Statistically significant after modified Bonferroni correction.

three models and 1% outliers in four models (defined as deviance residual < -2 or $> +2$). Due to the dichotomous outcome, the residuals were not expected to be normally distributed. Instead, we used our models to generate simulated data; visual comparison of actual versus simulated residuals revealed moderate deviations in the sepsis model and no deviations in other models.

Sensitivity Analyses

Patients who did not achieve hemostasis had undefined time to hemostasis and were excluded from the primary analysis, likely leading to survival bias. Therefore, two sensitivity analyses were performed including the 60 patients who exsanguinated before hemostasis was achieved. First, these patients were assigned time to hemostasis of 315 minutes, which was at the 95th percentile for time to hemostasis. After modified Bonferroni

correction, decreased time to hemostasis was significantly associated with decreased risk of mortality at 24 hours (RR, 0.93; 95% CI, 0.91–0.95) and 30 days (RR 0.95, 95% CI 0.93–0.96), as well as decreased risk of AKI (RR 0.97, 95% CI 0.96–0.99) and MOF (RR 0.94, 95% CI 0.91–0.97), but not ARDS (RR 1.00, 95% CI 0.96–1.03), sepsis (RR 0.99, 95% CI 0.97–1.03), or VTE (RR 1.02, 95% CI 0.97–1.07). Another sensitivity analysis was performed in which group assignment (Table 1) was substituted for time to hemostasis. After modified Bonferroni correction, decreasing group number was significantly associated with decreased mortality at 24 hours and 30 days, as well as decreased risk of MOF, but not AKI, ARDS, sepsis, or VTE.

DISCUSSION

We performed a prespecified secondary analysis of the PROPPR study and found no significant differences in rate of hemostasis between sites, but there was significant variability in time to hemostasis between sites. We also found significant variability in use of IR between sites and increased time to emergent IR compared to emergent OR, consistent with a previous report.¹⁶ Decreased time to hemostasis was independently associated with decreased incidence of 30-day mortality, AKI, ARDS, MOF, and sepsis, but not 24-hour mortality or VTE.

Components of hemostasis acquisition include recognition of significant hemorrhage, transport to the OR/IR suite, and the hemorrhage control procedure itself. Studies have reported improved outcomes with earlier time to operative^{7,8} or IR intervention⁹ in bleeding trauma patients. Several scoring methods have also been reported to rapidly identify bleeding patients in the trauma bay,^{17–19} and catheter-based interventions in conjunction with hybrid operating suites may further reduce delays in initiating appropriate therapy.²⁰ However, clinical benefit is ultimately achieved by acquiring earlier definitive hemorrhage control (i.e., hemostasis). Determinants of time to hemostasis after arrival to OR/IR include factors which are nonmodifiable (e.g., pattern of injury), modifiable (e.g., surgeons' skill level and judgment including decision for damage control vs. definitive therapy), and potentially modifiable (e.g., availability of hybrid operating capability). Previous studies have used time to OR/IR as a surrogate for time to hemostasis, which does not take into account the actual time required to perform definitive hemorrhage control maneuvers. In the present study, we found that time from OR/IR to hemostasis accounted for most of the overall time to hemostasis (Fig. 2).

Hemorrhagic death occurs rapidly with a median time to death of 2 hours to 3 hours after hospital arrival.^{4,5} Oyeniyi et al.²¹ performed a single-center retrospective study at a Level I center and found that trauma mortality from hemorrhage significantly decreased after implementation of significant changes in control of bleeding and early resuscitation procedures as part of a hemorrhage control bundle. These included earlier transfusion of plasma and platelets, earlier and increased use of temporizing hemorrhage control devices (extremity and junctional tourniquets, pelvic binders, hemostatic dressings, and resuscitative endovascular balloon occlusion of the aorta), and decreased time to OR/IR.^{6,22,23} We have previously argued that outcomes of clinical studies should be consistent with the disease process

being investigated, and have proposed using an outcome of all-cause mortality at 6 hours for future hemorrhage studies.²⁴ Given that purposeful action to effect earlier time to hemostasis will improve patient outcomes after trauma, the results of the current study support the use of time to hemostasis as a clinically significant endpoint for future hemorrhage studies. The overall complication rate was level until about 75 minutes, then steadily increased as time to hemostasis increased (Fig. 2). Time to hemostasis may serve as a quality metric for trauma centers, but further studies are needed to identify modifiable and potentially modifiable determinants of time to hemostasis as well as an optimal benchmark.

The limitations of this study are as follows. Importantly, we could not control for several factors impacting time to hemostasis. Some injury patterns, such as retrohepatic caval injuries, result in substantial and difficult-to-control hemorrhage, and such injury patterns are not recapitulated by ISS. Other factors affecting time to hemostasis include the surgeons' technical skill and judgment, including the decision to perform damage control versus definitive therapy and knowing when to ask for help. Although hemostasis was defined a priori in the PROPPR study as no bleeding requiring intervention in the surgical field or resolution of contrast blush in IR, it is to some degree subjective and consequently subject to bias, possibly accounting for some of the between-study site variability in time to hemostasis. Study sites also had significant differences in rates of blunt versus penetrating injury, which may have also contributed to variation in time to hemostasis. However, we believe that our method of mixed-effects regression (using study site as a random effect) accounts for this in our statistical models. Additionally, the ultimate goal of achieving early hemostasis is to reduce blood loss due to hemorrhage, but accurately measuring the volume of blood loss after trauma is prohibitively difficult. We have shown that time to hemostasis more accurately reflects the degree of blood loss compared with time to OR/IR, but time to hemostasis is nevertheless still a surrogate for volume of blood loss. Direct correlation between time to hemostasis and actual volume of blood loss is obfuscated by several factors including rate of hemorrhage. Interestingly, among all 680 patients in the PROPPR trial, the 1:1:1 group had increased *proportion* of hemostasis (86% vs. 78%, $p < 0.01$), but similar *time* to hemostasis (median, 144 minutes vs. 131 minutes; $p = 0.17$) compared with the 1:1:2 group,⁵ suggesting that higher plasma:RBC and platelet:RBC reduced the rate of hemorrhage instead of allowing clinicians to achieve hemostasis more rapidly. We used time to hemostasis as a continuous variable in our multivariable models, which necessarily excluded 60 (15%) patients who exsanguinated before hemostasis could be achieved, resulting in survivor bias. Sensitivity analyses which included these 60 patients still found significant associations between time to hemostasis versus mortality, MOF, and possibly AKI. In the primary analysis of 408 patients who achieved hemostasis, we demonstrated that increased time to hemostasis was associated with increased incidence of several posttraumatic complications which was further correlated with increased 30-day mortality. Given that it takes time for these complications to manifest, it makes sense that there was no correlation with 24-hour mortality. These limitations are counterbalanced by the strengths of this study, which include our method of mixed-effects analysis, correction for

multiple comparisons, and transparency in reporting diagnostics of our statistical tests.

In conclusion, time to hemostasis, but not rate of hemostasis, varied significantly between study sites in the PROPPR trial. Despite previous focus on time from hospital arrival to OR/IR, time from OR/IR to hemostasis accounts for the majority of overall time to hemostasis. Decreased time to hemostasis was independently associated with decreased 30-day mortality as well as incidence of AKI, ARDS, sepsis, and MOF. We find it biologically plausible that delayed hemostasis would result in increased blood loss, greater end organ ischemia, greater organ dysfunction, and increased late mortality. Time to hemostasis should be considered as an endpoint in future hemorrhage studies, and further studies investigating its use as a potential quality metric for trauma centers are warranted.

AUTHORSHIP

Study inception and design by RC, JDK, GVB, EEF, BAC, MJC, MAS, KB, EMB, KI, SR, JMP, CEW, and JBH. Data acquisition by JDK, GVB, EEF, BAC, MJC, MAS, KB, EMB, KI, SR, JMP, CEW, JBH, and PROPPR Study Group. Data analysis by RC, JDK, KJK, GVB, EEF, CEW, and JBH. All authors participated in manuscript preparation and critical appraisal.

ACKNOWLEDGMENTS

PROPPR Study Group:

Clinical Coordinating Center, University of Texas Health Science Center at Houston: John B. Holcomb, MD; Charles E. Wade, PhD; Deborah J. del Junco, PhD; Erin E. Fox, PhD; Nena Matijevic, PhD (Laboratory Committee co-Chair); Jeanette M. Podbielski, RN; Angela M. Beeler, BS.

Data Coordinating Center, University of Texas Health Science Center at Houston: Barbara C. Tilley, PhD; Sarah Baraniuk, PhD; Stacia M. DeSantis, PhD; Hongjian Zhu, PhD; Joshua Nixon, MS; Roann Seay, MS; Savitri N. Appana, MS; Hui Yang, MS; Michael O. Gonzalez, MS.

Core Laboratory, University of Texas Health Science Center at Houston: Lisa Baer, MS; Yao-Wei Willa Wang, MD; Brittany S. Hula, MS; Elena Espino, BS; An Nguyen, BS; Nicholas Pawelczyk, BS; Kisha D. Arora-Nutall, BS; Rishika Sharma, MD; Jessica C. Cardenas, PhD; Elaheh Rahbar, PhD; Tyrone Burnett, Jr., BS; David Clark, BS.

Resuscitation Outcomes Consortium, University of Washington: Gerald van Belle, PhD; Susanne May, PhD; Brian Leroux, PhD; David Hoyt, MD; Judy Powell, BSN, RN; Kellie Sheehan, BSN.

Systems Biology Committee, University of California, Berkeley: Alan Hubbard, PhD (co-Chair); Adam P. Arkin, PhD.

Transfusion Committee: John R. Hess, MD, MPH (co-Chair, University of Washington); Jeannie L. Callum, MD (co-Chair, Sunnybrook Health Sciences Centre).

Anesthesiology Committee: Jean-Francois Pittet, MD (Chair, University of Alabama at Birmingham).

Emergency Medicine Committee: Christopher N. Miller, MD (Chair, University of Cincinnati).

PROPPR Clinical Sites (listed in order of number of patients enrolled):

University of Texas Health Science Center at Houston: Bryan A. Cotton, MD, MPH; Laura Vincent, BSN, RN, CCRP; Timothy Welch; Tiffany Poole, DC; Evan G. Pivalizza, MD; Sam D. Gumbert, MD; Yu Bai, MD, PhD; James J. McCarthy, MD; Amy Noland, MD; Rhonda Hobbs, MT (ASCP)SBB.

University of Washington: Eileen M. Bulger, MD; Patricia Klotz, RN; Lindsay Cattin, BA; Keir J. Warner, BS; Angela Wilson, BA; David Boman, BA; Nathan White, MD, MS; Andreas Grabinsky, MD; Jennifer A. Daniel-Johnson, MBBS.

University of California, San Francisco: Mitchell Jay Cohen, MD (Systems Biology and Laboratory Committees co-Chair); Rachael A. Calcutt, MD, MSPH; Mary Nelson, RN, MPA; Brittney Redick, BA; Amanda Conroy, BA; Marc P. Steurer, MD, DESA; Preston C. Maxim, MD; Eberhard Fiebig, MD; Joanne Moore; Eireen Mallari, MT.

University of Cincinnati: Peter Muskat, MD; Jay A. Johannigman, MD; Bryce R. H. Robinson, MD; Richard D. Branson, MSc, RRT; Dina Goma, BS, RRT;

Christopher Barczak, BS, MT(ASCP); Suzanne Bennett, MD; Patricia M. Carey, MD; Helen Hancock, BS, MT(ASCP); Carolina Rodriguez, BA. University of Southern California: Kenji Inaba, MD; Jay G. Zhu, MD; Monica D. Wong, MS; Michael Menchine, MD, MPH; Kelly Katberg, MD, FACEP; Sean O. Henderson, MD; Rodney McKeever, MD; Ira A. Shulman, MD; Janice M. Nelson, MD; Christopher W. Tuma, BA, MT(ASCP), SBB; Cheryl Y. Matsushita, BS, MT(ASCP).

Shock, Trauma and Anesthesiology Research—Organized Research Center (STAR-ORC), R Adams Cowley Shock Trauma Center, University of Maryland Medical Center: Thomas M. Scalea, MD; Deborah M. Stein, MD, MPH; Cynthia K. Shaffer, MS, MBA; Christine Wade, BA; Anthony V. Herrera, MS; Seeta Kallam, MBBS; Sarah E. Wade, BS; Samuel M. Galvagno, Jr, DO, PhD; Magali J. Fontaine, MD, PhD; Janice M. Hunt, BS, MT(ASCP) SBB; Rhonda K. Cooke, MD.

University of Tennessee Health Science Center, Memphis: Timothy C. Fabian, MD; Jordan A. Weinberg, MD; Martin A. Croce, MD; Suzanne Wilson, RN; Stephanie Panzer-Baggett, RN; Lynda Waddle-Smith, BSN; Sherri Flax, MD. Medical College of Wisconsin: Karen J. Brasel, MD, MPH; Pamela Walsh, AS, CCRP; David Milia, MD; Allia Nelson, BS, BA; Olga Kaslow, MD, PhD; Tom P. Aufderheide, MD, MS; Jerome L. Gottschall, MD; Erica Carpenter, MLS (ASCP). University of Arizona: Terence O'Keeffe, MBChB, MSPH; Laurel L. Rokowski, RN, BSN, MKT; Kurt R. Denninghoff, MD; Daniel T. Redford, MD; Deborah J. Novak, MD; Susan Knoll, MS, MT (ASCP) SBB.

University of Alabama at Birmingham: Jeffrey D. Kerby, MD, PhD; Patrick L. Bosarge, MD; Albert T. Pierce, MD; Carolyn R. Williams, RN, BSN, BSME; Shannon W. Stephens, EMTP; Henry E. Wang, MD, MS; Marisa B. Marques, MD.

Oregon Health and Science University: Martin A. Schreiber, MD; Jennifer M. Watters, MD; Samantha J. Underwood, MS; Tahnee Groat, MPH; Craig Newgard, MD, MPH; Matthias Merkel, MD, PhD; Richard M. Scanlan, MD; Beth Miller, MT (ASCP) SBB.

Sunnybrook Health Sciences Centre: Sandro Rizoli, MD, PhD; Homer Tien, MD; Barto Nascimento, MD, MSc, CTBS; Sandy Trpcic; Skeeta Sobrian-Couroux, RN, CCRP, BHA; Marciano Reis; Adic Pe'rez, MD; Susan E. Belo, MD, PhD; Lisa Merkley, BA, MLT, CBT; Connie Colavecchia, BSc, MLT.

DISCLOSURE

B.A.C. is a paid consultant to Haemonetics Corp. S.R. reported receiving grant funding from TEM International and CSL Behring. Otherwise, authors report no conflicts of interest.

The Pragmatic Randomized Optimal Platelet and Plasma Ratio (PROPPR) trial was sponsored by the U.S. National Heart, Lung, and Blood Institute (U01HL077863) and the U.S. Department of Defense. RC is supported by a T32 fellowship (grant 5T32GM008792) from the National Institute of General Medical Sciences.

REFERENCES

1. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, Pons PT. Epidemiology of trauma deaths: a reassessment. *J Trauma*. 1995;38(2):185–193.
2. Harvin JA, Maxim T, Inaba K, Martinez-Aguilar MA, King DR, Choudhry AJ, Zielinski MD, Akinyeye S, Todd SR, Griffin RL, et al. Mortality after emergent trauma laparotomy: a multicenter, retrospective study. *J Trauma Acute Care Surg*. 2017;83(3):464–468.
3. Kotwal RS, Montgomery HR, Kotwal BM, Champion HR, Butler FK Jr, Mabry RL, Cain JS, Blackbourne LH, Mechler KK, Holcomb JB. Eliminating preventable death on the battlefield. *Arch Surg*. 2011;146(12):1350–1358.
4. Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, Schreiber MA, Alarcon LH, Bai Y, Brasel KJ, Bulger EM, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. *JAMA Surg*. 2013;148:127–136.
5. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA*. 2015;313:471–482.
6. Chang R, Holcomb JB. Optimal fluid therapy for traumatic Hemorrhagic shock. *Crit Care Clin*. 2017;33(1):15–36.
7. Clarke JR, Trooskin SZ, Doshi PJ, Greenwald L, Mode CJ. Time to laparotomy for intra-abdominal bleeding from trauma does affect survival for delays up to 90 minutes. *J Trauma*. 2002;52(3):420–425.
8. Meizoso JP, Ray JJ, Karcutskie CA4th, Allen CJ, Zakrisson TL, Pust GD, Koru-Sengul T, Ginzburg E, Pizano LR, Schulman CI, et al. Effect of time to operation on mortality for hypotensive patients with gunshot wounds to the torso: the golden 10 minutes. *J Trauma Acute Care Surg*. 2016;81(4):685–691.
9. Schwartz DA, Medina M, Cotton BA, Rahbar E, Wade CE, Cohen AM, Beeler AM, Burgess AR, Holcomb JB. Are we delivering two standards of care for pelvic trauma? Availability of angioembolization after hours and on weekends increases time to therapeutic intervention. *J Trauma Acute Care Surg*. 2014;76(1):134–139.
10. Radwan ZA, Bai Y, Matijevic N, del Junco DJ, McCarthy JJ, Wade CE, Holcomb JB, Cotton BA. An emergency department thawed plasma protocol for severely injured patients. *JAMA Surg*. 2013;148(2):170–175.
11. Cannon JW, Khan MA, Raja AS, Cohen MJ, Como JJ, Cotton BA, Dubose JJ, Fox EE, Inaba K, Rodriguez CJ, et al. Damage control resuscitation in patients with severe traumatic hemorrhage: a practice management guideline from the Eastern Association for the Surgery of Trauma. *J Trauma Acute Care Surg*. 2017;82(3):605–617.
12. Nascimben B, Rizoli S, Rubenfeld G, Lin Y, Callum J, Tien HC. Design and preliminary results of a pilot randomized controlled trial on a 1:1:1 transfusion strategy: the trauma formula-driven versus laboratory-guided study. *J Trauma*. 2011;71(5 Suppl 1):S418–S426.
13. Undurraga Perl VJ, Leroux B, Cook MR, Watson J, Fair K, Martin DT, Kerby JD, Williams C, Inaba K, Wade CE, et al. Damage-control resuscitation and emergency laparotomy: findings from the PROPPR study. *J Trauma Acute Care Surg*. 2016;80(4):568–574.
14. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. *JAMA*. 2012;307(23):2526–2533.
15. Yelland LN, Salter AB, Ryan P. Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data. *Am J Epidemiol*. 2011;174(8):984–992.
16. Chang R, Fox EE, Greene TJ, Eastridge BJ, Gilani R, Chung KK, DeSantis SM, DuBose JJ, Tomasek JS, Fortuna GR Jr, et al. Multicenter retrospective study of non-compressible torso hemorrhage: anatomic locations of bleeding and comparison of endovascular versus open approach. *J Trauma Acute Care Surg*. 2017;83(1):11–18.
17. Schreiber MA, Perkins J, Kiraly L, Underwood S, Wade C, Holcomb JB. Early predictors of massive transfusion in combat casualties. *J Am Coll Surg*. 2007;205(4):541–545.
18. Yücel N, Lefering R, Maegele M, Vorweg M, Tjardes T, Ruchholtz S, Neugebauer EA, Wappler F, Bouillon B, Rixen D, Polytrauma Study Group of the German Trauma Society. Trauma Associated Severe Hemorrhage (TASH)-score: probability of mass transfusion as surrogate for life threatening hemorrhage after multiple trauma. *J Trauma*. 2006;60(6):1228–1236.
19. Cotton BA, Dossett LA, Haut ER, Shafi S, Nunez TC, Au BK, Zaydfudim V, Johnston M, Arbogast P, Young PP. Multicenter validation of a simplified score to predict massive transfusion in trauma. *J Trauma*. 2010;69(Suppl 1):S33–S39.
20. Holcomb JB, Fox EE, Scalea TM, Napolitano LM, Albarado R, Gill B, Dunkin BJ, Kirkpatrick AW, Cotton BA, Inaba K, et al. Current opinion on catheter-based hemorrhage control in trauma patients. *J Trauma Acute Care Surg*. 2014;76(3):888–893.
21. Oyeniyi BT, Fox EE, Scerbo M, Tomasek JS, Wade CE, Holcomb JB. Trends in 1029 trauma deaths at a level 1 trauma center: impact of a bleeding control bundle of care. *Injury*. 2017;48(1):5–12.
22. Shrestha B, Holcomb JB, Camp EA, Del Junco DJ, Cotton BA, Albarado R, Gill BS, Kozar RA, Kao LS, McNutt MK, et al. Damage-control resuscitation increases successful nonoperative management rates and survival after severe blunt liver injury. *J Trauma Acute Care Surg*. 2015;78(2):336–341.
23. Johansson PI, Stensballe J, Oliveri R, Wade CE, Ostrowski SR, Holcomb JB. How I treat patients with massive hemorrhage. *Blood*. 2014;124(20):3052–3058.
24. Fox EE, Holcomb JB, Wade CE, Bulger EM, Tilley BC, PROPPR Study Group. Earlier endpoints are required for hemorrhagic shock trials among severely injured patients. *Shock*. 2017;47(5):567–573.